Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > March 2, 2023
Daily News
March 2, 2023
- Komeito Petitions Govt for Market Incentives for Meiji’s Novel Antibacterial
March 2, 2023
- LDP League to Compile Final Proposal for SaMD Reimbursement This Spring
March 2, 2023
- Neil MacGregor Takes Over as President of Amgen Japan
March 2, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
- Eylea 8 mg Filed in Japan to Extend Dosing Intervals: Bayer
March 2, 2023
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…